ICON Wins Best CRO at the Vaccine Industry Excellence Awards
07 Outubro 2020 - 6:00AM
Business Wire
Award recognises ICON’s long-standing
vaccine development expertise
ICON plc, (NASDAQ: ICLR) a global provider of outsourced
drug and device development and commercialisation services to
pharmaceutical, biotechnology, medical device industries and
government and public health organisations, today announced it has
been awarded Best Clinical Research Organisation (CRO) at the
Vaccine Industry Excellence (ViE) Awards. ICON was presented with
the award at the World Vaccine Congress which took place virtually
last week.
The ViE awards were created to honour and recognise the efforts,
accomplishments, and positive contributions of companies and
individuals in the vaccine industry. ICON was voted Best CRO by
industry leaders asked to name their preferred CRO, and confirmed
by a final judgement from a Scientific Advisory Board.
This marks the third time ICON has won the award. The company
was awarded ViE Best CRO in 2017 and 2014, and has been named as a
finalist every year since 2011, demonstrating a long history of
excellence in vaccine research.
“We are extremely proud to be recognised as the world’s best CRO
for vaccine development,” commented Dr Steve Cutler, ICON’s Chief
Executive Officer. “The importance of vaccine research is more
apparent now than ever before, with all eyes on the industry as the
world waits in hope. This award is recognition of the continued
hard work and dedication of the ICON vaccines team.”
Since February, ICON has mobilised its vaccine resources to
address the COVID-19 global threat, including its ability to
conduct home-based trials to minimise infection. The company is
currently providing clinical monitoring and safety oversight on
more than 100 COVID-19 trials for both the private and government
sectors. These include a prophylactic vaccine study in healthy
participants, and a study investigating antiviral treatment for
patients with confirmed Coronavirus infection. ICON has conducted
more than 246 vaccine studies globally, including over 40 studies
in respiratory viruses, within the past five years alone.
ICON offers a fully integrated vaccine clinical development
solution, from preclinical and laboratory services to comparative
effectiveness using interventional, observational, and pragmatic
methods. ICON’s services span the entire lifecycle of product
development and can be adapted to suit small local trials or large
global programmes. Prior to the COVID-19 pandemic, ICON’s vaccines
team worked on trials involving the Ebola Virus, as well as earlier
SARS (severe acute respiratory syndrome) and MERS (Middle East
respiratory syndrome) outbreaks, on behalf of governments and NGOs,
global biotech and pharmaceutical industry partners.
More information is available at www.iconplc.com/covid-19 and
www.iconplc.com/vaccines.
A full list of ICON’s industry awards can be viewed at
www.iconplc.com/awards.
About ICON plc
ICON plc is a global provider of outsourced drug and device
development and commercialisation services to pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic
development, management and analysis of programs that support
clinical development - from compound selection to Phase I-IV
clinical studies. With headquarters in Dublin, Ireland, ICON
currently operates from 94 locations in 40 countries and has
approximately 15,150 employees as of June 30, 2020.
Further information is available at www.iconplc.com.
This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and
industry conditions. These statements are not guarantees of future
performance or actual results, and actual results, developments and
business decisions may differ from those stated in this press
release. The forward-looking statements are subject to future
events, risks, uncertainties and other factors that could cause
actual results to differ materially from those projected in the
statements, including, but not limited to, the ability to enter
into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the
integration of new business mergers and acquisitions, the impact of
COVID-19 on our business, as well as other economic and global
market conditions and other risks and uncertainties detailed from
time to time in SEC reports filed by ICON, all of which are
difficult to predict and some of which are beyond our control. For
these reasons, you should not place undue reliance on these
forward-looking statements when making investment decisions. The
word "expected" and variations of such words and similar
expressions are intended to identify forward-looking statements.
Forward-looking statements are only as of the date they are made
and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information,
future events or otherwise. More information about the risks and
uncertainties relating to these forward-looking statements may be
found in SEC reports filed by ICON, including its Form 20-F, F-1,
S-8 and F-3, which are available on the SEC's website at
http://www.sec.gov.
ICON/ICLR-G
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201007005398/en/
ICON Media Contact Gareth Arnold Weber Shandwick
Telephone: (+44) 07944 688281 GArnold@webershandwick.com
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
ICON (NASDAQ:ICLR)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024